Press release
Treg Cell-Based Therapies Clinical Trial Landscape Expands With 55+ Emerging Therapies, Reveals DelveInsight
Treg Cell-Based Therapies Clinical Trial
DelveInsight's most recent evaluation underscores the accelerated global momentum in the Treg Cell-Based Therapies domain, with over 51 companies collectively developing more than 55 therapeutic assets. The report offers an in-depth analysis of active clinical studies, scientific mechanisms, routes of administration, development approaches, and the broader scientific and commercial initiatives fueling innovation within this evolving therapeutic area.
Request a free sample report: https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Treg Cell-Based Therapies Pipeline Report
• An increasing number of biopharmaceutical organizations across the globe are investing in next-generation Treg-focused immunotherapies, contributing to consistent advancement in the field.
• Prominent companies driving development include HCW Biologics, Sangamo Therapeutics, Gentibio, Abata Therapeutics, NightHawk Biosciences, Quell Therapeutics, Coya Therapeutics, Orca Bio, Caladrius Biosciences, VT BIO, Cellenkos, among others.
• Several clinical and preclinical assets-such as HCW9302, KITE-037, GNTI-122, ABA-101, PTX-35, TX200, QEL-001, Coya 101, Orca-T, CLBS03, VT301, and CK0804-are expected to play a pivotal role in shaping future market dynamics.
• October 2024: Quell Therapeutics entered a collaboration with eXmoor Pharma to enable GMP manufacturing of its CAR-Treg candidates at eXmoor's newly established gene and cell therapy facility in the UK.
• September 2024: Abata Therapeutics received FDA Fast Track designation for ABA-101, its autologous Treg therapy being developed for progressive multiple sclerosis.
• September 2024: PolTREG S.A. was granted a patent by China's National Intellectual Property Administration for its intrathecal delivery approach for cellular therapies targeting multiple sclerosis.
• May 2024: Orca Bio shared updated clinical insights on Orca-T, its lead allogeneic T-cell immunotherapy, during the ASCO 2024 Annual Meeting.
Overview of Treg Cell-Based Therapies
Treg cell-based therapies utilize regulatory T cells to restore immune homeostasis in autoimmune and inflammatory conditions. By naturally suppressing excessive immune responses, Tregs provide a robust and durable immunomodulatory strategy, positioning these therapies as a potentially transformative option for managing chronic immune-mediated disorders.
Access a free sample PDF report to explore the Treg Cell-Based Therapies Pipeline Therapeutic Assessment: https://www.delveinsight.com/report-store/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Prominent Treg Cell-Based Therapies Pipeline Candidates
Key therapies progressing through various stages of clinical development include:
• HCW9302 - HCW Biologics
• KITE-037 - Sangamo Therapeutics
• GNTI-122 - Gentibio
• ABA-101 - Abata Therapeutics
• PTX-35 - NightHawk Biosciences
• TX200 - Sangamo Therapeutics
• QEL-001 - Quell Therapeutics Limited
• Coya 101 - Coya Therapeutics
• Orca-T - Orca Bio
• CLBS03 - Caladrius Biosciences
• VT301 - VT BIO
• CK0804 - Cellenkos
Treg Cell-Based Therapies Pipeline Therapeutics Assessment
• Evaluation by product classification
• Analysis by development stage and product type
• Assessment by route of administration
• Breakdown by development stage and administration route
• Evaluation by molecule type
• Analysis by stage and molecular category
DelveInsight's Treg Cell-Based Therapies report profiles approximately 55+ therapeutic candidates across multiple stages of development, including:
• Late-stage programs (Phase III)
• Mid-stage programs (Phase II)
• Early-stage programs (Phase I)
• Preclinical and discovery-stage candidates
• Discontinued and inactive programs
• Route of administration insights
Additional product-level insights are detailed within the report.
Download the Treg Cell-Based Therapies pipeline analysis to gain deeper visibility into emerging treatment approaches:
https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Companies in the Treg Cell-Based Therapies Market
Leading participants in the Treg Cell-Based Therapeutics space include Rapa Therapeutics, Orca Bio, Caladrius Biosciences, Sangamo Therapeutics, Quell Therapeutics, Coya Therapeutics, Sonoma Biotherapeutics, GentiBio, AstraZeneca, TCR2 Therapeutics, Cellenkos, VT BIO, KSQ Therapeutics, Kyverna Therapeutics, Astellas, Abata Therapeutics, TRACT Therapeutics, Adaptive Biotechnologies, PolTREG, TeraImmune, and others.
Treg Cell-Based Therapies Market Dynamics
Market Drivers:
• Increasing prevalence of autoimmune and inflammatory disorders
• Ongoing advancements in next-generation T-cell engineering technologies
Market Barriers:
• Elevated manufacturing and treatment costs
• Complex and resource-intensive production processes for Treg-based therapies
Download a free sample PDF report to learn more about Treg Cell-Based Therapies drugs and treatment strategies: https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the "Treg Cell-Based Therapies Pipeline Insight, 2025" Report
• Geographical Coverage: Global
• Key Companies: HCW Biologics, Sangamo Therapeutics, Gentibio, Abata Therapeutics, NightHawk Biosciences, Quell Therapeutics Limited, Coya Therapeutics, Orca Bio, Caladrius Biosciences, VT BIO, Cellenkos, and others
• Key Therapies: HCW9302, KITE-037, GNTI-122, ABA-101, PTX-35, TX200, QEL-001, Coya 101, Orca-T, CLBS03, VT301, CK0804, and others
• Therapeutic Assessment: Currently available and emerging Treg Cell-Based Therapies
• Market Dynamics: Key growth drivers and challenges shaping the Treg Cell-Based Therapies market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Treg Cell-Based Therapies Clinical Trial Landscape Expands With 55+ Emerging Therapies, Reveals DelveInsight here
News-ID: 4346985 • Views: …
More Releases from DelveInsight Business Research
Colorectal Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Colorectal Cancer pipeline constitutes 195+ key companies continuously working towards developing 200+ Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Colorectal Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Colorectal Cancer Market.
The Colorectal…
Dementia Market: Growth Momentum Across 7MM to 2034 - DelveInsight
DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dementia Market Forecast
https://www.delveinsight.com/sample-request/dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Dementia…
Eosinophilic Esophagitis Pipeline 2025: Therapies Under Investigation, Clinical …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Eosinophilic Esophagitis pipeline constitutes 25+ key companies continuously working towards developing 30+ Eosinophilic Esophagitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Eosinophilic Esophagitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Eosinophilic Esophagitis Market.
The Eosinophilic Esophagitis…
Follicular Lymphoma Market: Expanding Revenue Landscape to 2034 - DelveInsight
FelveInsight's "Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Follicular Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Follicular Lymphoma Market Forecast
https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Therapeutic
Exosome Therapeutic Market : Detailed Overview
Introduction:
The exosome therapeutic market is a rapidly emerging segment in the field of regenerative medicine and drug delivery. Exosomes are extracellular vesicles naturally released by cells that play a crucial role in cell communication and genetic material transfer. They have gained attention for their potential applications in treating various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. As a novel therapeutic platform, exosomes provide significant advantages such as low immunogenicity,…
Parkinson's Disease Therapeutic Market Hope for Patients: The Parkinson's Diseas …
Parkinson's Disease Therapeutic Market worth $6.51 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Parkinson's Disease Therapeutic Market - (By Drugs (Carbidopa-levodopa, Dopamine agonists, Mao-b inhibitors, COMT inhibitors, Anticholinergics, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), By Brand (Branded, Generics), By Route of Administration (Oral, Injectable, Intestinal Infusion, Subcutaneous, Others)),…
Global Remote Therapeutic Monitoring Market
According to a new market research report published by Global Market Estimates, the Global Remote Therapeutic Monitoring Market is projected to grow at a CAGR of 17.4% from 2023 to 2028.
Medsien, Intellihinc, Zimmer Biomet, Owlytics Healthcare, Limber Health, Medistics, RxCap, Propeller Health, HealthArc, CENSON Health, and B Castle Smith & Co., are some of the key players in the remote therapeutic monitoring market.
Browse 147 Market Data Tables and 115…
Europe Digital Therapeutic (DTx) Market
Europe Digital Therapeutic (DTx) Market report provides information about the industry, including valuable Analysis and Detailed study. This research study explores the Global Europe Digital Therapeutic (DTx) Market in detail such as industry chain structures, raw material suppliers, with manufacturing. The Europe Digital Therapeutic (DTx) market examines the primary segments of the market. This intelligent study provides historical data from forecast.It also provides the details such as whether the customers…
Recombinant Therapeutic Antibodies and Proteins Market continues to expand with …
Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies…
Therapeutic Vaccine Market 2020 - 2028 Top Companies Agenus Inc., Argos Therapeu …
This detailed market study covers therapeutic vaccine market growth potentials which can assist the stake holders to understand key trends and prospects in therapeutic vaccine market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The…
